Target Name: GP1BB
NCBI ID: G2812
Other Name(s): glycoprotein Ib platelet beta subunit | GPIb-beta | nuclear localization signal deleted in velocardiofacial syndrome | CD42C | GP1BB_HUMAN | GPIBB | GP-Ib beta | GPIbB | antigen CD42b-beta | CD42b-beta | Platelet glycoprotein Ib beta chain | truncated platelet membrane glycoprotein Ib beta | BS | CD42c | BDPLT1 | Antigen CD42b-beta | glycoprotein Ib (platelet), beta polypeptide | GPIbbeta | glycoprotein Ib platelet subunit beta | platelet membrane glycoprotein Ib beta | CD_antigen: CD42c | Glycoprotein Ib platelet subunit beta

GP1BB-Based Biomarkers for Cardiovascular Disease

Glycoprotein (GP) is a protein that is expressed in various cell types of the body, including platelets. GP1BB is a specific subunit of the GP protein that is expressed in platelets, and it is involved in the regulation of platelet function. GP1BB has been identified as a potential drug target and a biomarker for various cardiovascular diseases, including thrombosis, myocardial infarction, and stroke.

Current Treatment Strategies

Currently, there are limited treatment options available for individuals with GP1BB-related diseases. The only treatment that is specifically targeted at GP1BB is the drug Xadruna, which is a recombinant GP1BB protein that is designed to prevent platelet aggregation. Xadruna is used to prevent deep vein thrombosis (DVT), and it has been shown to be effective in clinical trials.

Despite the effectiveness of Xadruna, there is still a need for more effective and targeted treatments for individuals with GP1BB-related diseases. This is where GP1BB-based biomarkers can be useful. By using GP1BB as a biomarker, researchers can identify individuals who are at risk for developing certain cardiovascular diseases and target those individuals with more effective treatments.

Biomarker Assays

One of the most promising biomarkers for GP1BB is its ability to trigger an immune response. Researchers have shown that when GP1BB is exposed to its ligand, it can induce an immune response that is characterized by an increase in the levels of certain cytokines, such as TNF-alpha, IL-8, and IFN-gamma.

This immune response is important because it can be used to identify individuals who are at risk for developing cardiovascular diseases. For example, individuals who have a history of cardiovascular disease or who have certain risk factors, such as a family history of cardiovascular disease or high blood pressure, may be more likely to develop an immune response to GP1BB.

Another biomarker that has been shown to be associated with GP1BB is the level of GP1BB in the blood. Researchers have shown that individuals with higher levels of GP1BB in their blood are more likely to develop cardiovascular disease. This biomarker can be used to identify individuals who are at risk for developing cardiovascular disease and target those individuals with more effective treatments.

Targeting GP1BB

GP1BB has been identified as a potential drug target because it is involved in the regulation of platelet function, which is a critical factor in the development of cardiovascular disease. By targeting GP1BB, researchers can develop new treatments that will be more effective in preventing and treating cardiovascular disease.

One of the most promising approaches to targeting GP1BB is the use of small molecules. Researchers have shown that a number of small molecules have been shown to be able to inhibit the activity of GP1BB, and that these molecules may be effective in preventing or treating cardiovascular disease disease.

Another approach to targeting GP1BB is the use of monoclonal antibodies (MCAs). MCAs are laboratory-produced antibodies that are designed to recognize and bind to a specific protein, such as GP1BB. MCAs have been shown to be effective in targeting GP1BB and may be a useful addition to the treatment options available for individuals with GP1BB-related diseases.

Conclusion

GP1BB is a protein that is involved in the regulation of platelet function and has been identified as a potential drug target for cardiovascular disease. While currently there are limited treatment options available for individuals with GP1BB-related diseases, GP1BB-based biomarkers can be used to identify individuals who are at risk for developing certain cardiovascular diseases and target those individuals with more effective treatments. Additionally, small molecules and MCAs have been shown to be effective in targeting GP1BB, and further research is needed to develop new treatments for individuals with GP1BB- related diseases.

Protein Name: Glycoprotein Ib Platelet Subunit Beta

Functions: Gp-Ib, a surface membrane protein of platelets, participates in the formation of platelet plugs by binding to von Willebrand factor, which is already bound to the subendothelium

More Common Targets

GP2 | GP5 | GP6 | GP9 | GPA33 | GPAA1 | GPALPP1 | GPAM | GPANK1 | GPAT2 | GPAT3 | GPAT4 | GPATCH1 | GPATCH11 | GPATCH2 | GPATCH2L | GPATCH3 | GPATCH4 | GPATCH8 | GPBAR1 | GPBP1 | GPBP1L1 | GPC1 | GPC1-AS1 | GPC2 | GPC3 | GPC4 | GPC5 | GPC5-AS1 | GPC5-AS2 | GPC6 | GPC6-AS1 | GPC6-AS2 | GPCPD1 | GPD1 | GPD1L | GPD2 | GPER1 | GPHA2 | GPHB5 | GPHN | GPI | GPI transamidase complex | GPI-GlcNAc transferase complex | GPIHBP1 | GPKOW | GPLD1 | GPM6A | GPM6B | GPN1 | GPN2 | GPN3 | GPNMB | GPR101 | GPR107 | GPR108 | GPR119 | GPR12 | GPR132 | GPR135 | GPR137 | GPR137B | GPR137C | GPR139 | GPR141 | GPR142 | GPR143 | GPR146 | GPR148 | GPR149 | GPR15 | GPR150 | GPR151 | GPR152 | GPR153 | GPR155 | GPR156 | GPR157 | GPR158 | GPR158-AS1 | GPR15LG | GPR160 | GPR161 | GPR162 | GPR17 | GPR171 | GPR173 | GPR174 | GPR176 | GPR179 | GPR18 | GPR180 | GPR182 | GPR183 | GPR19 | GPR199P | GPR20 | GPR21 | GPR22 | GPR25